Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.25 estudios en Dermatología (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate the effectiveness of PCS499 at 6 Months in treating ulcerations in patients who have necrobiosis lipoidica. C. Albicans during Early Life Predisposes Individuals to Atopy Rochester, Minn. The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis. We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations. A Study to Define Axl Expression Level in Skin Biopsy Specimens from Patients with Skin Cancer in Relation to Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to define the presence and role of Axl in the risk of skin cancers in patients with CLL as well as non-CLL patients. A Study to Evaluate Dupilumab as a Treatment for Moderate-to-Severe, Chronic Hepatic Pruritus Jacksonville, Fla. The purpose of this study is to investigate the potential effectiveness of dupilumab in the treatment of moderate-to-severe, chronic hepatic pruritus. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). A Study to Evaluate Perceptions of Midline Sternotomy Scar in Children and Young Adults Rochester, Minn. The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? A Study of DNA Markers for the Detection of Metastatic Melanoma in Blood Rochester, Minn. The purpose of this study is to discover and validate DNA methylation-based markers that identify patients with metastatic melanoma based on the detection of such markers in patient blood with the ultimate goal of using blood-based multi-marker testing as a method of disease surveillance in melanoma patients. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Jacksonville, Fla. The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma following complete resection. Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Scottsdale/Phoenix, Ariz. The purpose of this study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study is to compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT -To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT; to evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT; to assess cemiplimab pharmacokinetics and immunogenicity in human serum. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 11 Ir a página 22 Ir a página 33 SiguientePróxima página Solicite una consulta Grupos especializadosInvestigación June 21, 2024 Comparte en: FacebookTwitter DermatologíaSeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos & seguro médicoNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos & seguro médicoNoticias de Mayo ClinicRemisiones ORG-20420337 Centros y departamentos médicos Dermatología